Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Medicare Rx Plans: Oral Chemo, Self-Injectables May Be Fallback

Executive Summary

Legislation extending Medicare coverage to oral chemotherapy drugs and self-injectables is among the fallback steps under consideration in the Senate Finance Committee if Congress fails to pass a comprehensive drug benefit this year

You may also be interested in...



Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit

Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress

Medicare Rx Positioning For 2003: Merck Prepares Investors For Benefit

Merck is telling investors to expect a "meaningful" Medicare prescription drug benefit in the 108th Congress

Rx Pricing Attacks Fail In Key House Races; Medicare Rx Vote Protects GOP

The House leadership is unlikely to change its approach to Medicare prescription drug coverage and pharmaceutical pricing following the Republican victories in the mid-term elections Nov. 5

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040482

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel